Clinical Trial Update: Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update exploring S-1 combined with DC+CIK as maintenance therapy for advanced pancreatic ductal adenocarcinoma, status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma
• Solid Tumor

Drugs mentioned

• DC-CIK
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: University of Malaya | Conditions: Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor | Phase 2, Phase 3 | Status: UNKNOWN